Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Stopped Interim monitoring
Conditions
- Endometrial Clear Cell Adenocarcinoma
- Ovarian Clear Cell Cystadenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Uterine Corpus Cancer
Interventions
- DRUG: Dasatinib
- OTHER: Laboratory Biomarker Analysis
Sponsor
National Cancer Institute (NCI)
Collaborators